Unicycive Therapeutics (UNCY) Treasury Shares (2021 - 2026)
Unicycive Therapeutics posted quarterly Treasury Shares of $478419.0 for Q1 2026, down 90.0% year-on-year from $4.8 million in Q1 2025, and little changed on a QoQ basis from $478419.0 in Q4 2025.
Unicycive Therapeutics (UNCY) has 6 years of Treasury Shares data on file, last reported at $478419.0 in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares fell 90.0% year-over-year to $478419.0; the trailing twelve-month figure through Mar 2026 stood at $478419.0 (down 90.0% YoY), and the FY2025 full-year result was $478419.0, changed 0.0% from the prior year.
- Treasury Shares for Q1 2026 stood at $478419.0, roughly flat from $478419.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $11.9 million in Q2 2023 and bottomed at $352938.0 in Q1 2023.
- The 5-year median for Treasury Shares is $1.6 million (2023), against an average of $3.2 million.
- The widest annual swing landed in 2024, when Treasury Shares surged 1255.53%; it then plunged 93.56% in 2025.
- A 5-year view of Treasury Shares shows it stood at $389676.0 in 2022, then surged by 1127.74% to $4.8 million in 2023, then plunged by 90.0% to $478419.0 in 2024, then changed by 0.0% to $478419.0 in 2025, then changed by 0.0% to $478419.0 in 2026.
- The last three Treasury Shares figures came in at $478419.0 (Q1 2026), $478419.0 (Q4 2025), and $478419.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 265,401.92 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 700,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 34.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 478,419.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 478,419.00 |
| Mar 31, 2026 | 478,419.00 |
| Dec 31, 2025 | 478,419.00 |
| Dec 31, 2025 | 478,419.00 |
| Sep 30, 2025 | 478,419.00 |
| Sep 30, 2025 | 478,419.00 |
| Jun 30, 2025 | 478,419.00 |
| Jun 30, 2025 | 478,419.00 |
| Mar 31, 2025 | 4.78 Mn |
| Mar 31, 2025 | 4.78 Mn |
| Dec 31, 2024 | 478,419.00 |
| Dec 31, 2024 | 478,419.00 |
| Sep 30, 2024 | 7.43 Mn |
| Sep 30, 2024 | 7.43 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Mar 31, 2024 | 4.78 Mn |
| Mar 31, 2024 | 4.78 Mn |
| Dec 31, 2023 | 4.78 Mn |
| Dec 31, 2023 | 4.78 Mn |
| Sep 30, 2023 | 2.80 Mn |
| Sep 30, 2023 | 2.80 Mn |
| Jun 30, 2023 | 11.87 Mn |
| Jun 30, 2023 | 11.87 Mn |
| Mar 31, 2023 | 352,938.00 |
| Mar 31, 2023 | 352,938.00 |
| Dec 31, 2022 | 389,676.00 |
| Dec 31, 2022 | 389,676.00 |
| Dec 31, 2021 | 674,176.00 |
| Dec 31, 2021 | 674,176.00 |